KEVIN GAREY to Administration, Oral
This is a "connection" page, showing publications KEVIN GAREY has written about Administration, Oral.
Connection Strength
0.689
-
A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk. J Infect Dis. 2025 Dec 20; 232(6):1446-1456.
Score: 0.201
-
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial. J Antimicrob Chemother. 2025 Oct 03; 80(10):2719-2726.
Score: 0.198
-
A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 12 01; 75(12):3635-3643.
Score: 0.142
-
A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012 Feb; 32(2):129-34.
Score: 0.077
-
Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000 Dec; 118(6):1826-7.
Score: 0.035
-
Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review. Nutr Clin Pract. 2016 Apr; 31(2):171-9.
Score: 0.025
-
Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005 Apr; 27(2):81-2.
Score: 0.012